Abbott launches consumer biowearable
By HME News Staff
Updated 8:37 AM CDT, Mon September 9, 2024
ABBOTT PARK, Ill. - Abbott has announced the U.S. availability of Lingo, the company’s first glucose monitoring system available without prescription.
The Lingo system includes a biosensor and a mobile app designed for consumers who want to improve their overall health and wellness, the company says.
"There is a great deal of interest in tracking biomarkers that provide insights into one's health and wellness that were previously undetectable using the trackers available to consumers," said Olivier Ropars, divisional vice president of Abbott's Lingo business. "Glucose is a powerful signal of your body's unique response to food and lifestyle. Abbott's Lingo tracks your glucose 24/7, translating the data into insights and bridging the gap between traditional healthcare and preventative measures. Lingo empowers individuals to build new healthy habits and take control of their health and wellness."
Lingo is based on Abbott’s FreeStyle Libre CGM technology, which is now used by more than 6 million people with diabetes globally.
The system, which tracks glucose in real time and provides personal insights and coaching, is available for consumers 18 years and older not on insulin. Abbott announced in June that Lingo had been cleared by the U.S. Food and Drug Administration.
-
Earlier this year, Dexcom received clearance from the U.S. Food and Drug Administration for its Stelo by Dexcom, a continuous glucose monitor that will be available for people with Type 2 diabetes without a prescription.
Comments